Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an announcement.
Clarity Pharmaceuticals has issued 48,485,212 new fully paid ordinary shares at $4.20 each, as part of an equity raising initiative targeting institutional investors. This move, executed under the company’s available capacity per ASX Listing Rule 7.1, aims to bolster Clarity’s financial position, potentially enhancing its market presence and operational capabilities in the radiopharmaceutical industry.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.20 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company specializing in the treatment of serious diseases. It is a leader in innovative radiopharmaceuticals, focusing on developing Targeted Copper Theranostics using its SAR Technology Platform for cancer treatment.
Average Trading Volume: 3,098,329
Technical Sentiment Signal: Buy
Current Market Cap: A$1.4B
See more insights into CU6 stock on TipRanks’ Stock Analysis page.